The first of its kind in the world, our registeries hold 15 years of data on ophthalmic treatment outcomes for neovascular (wet) age-related macular degeneration (wet AMD).
Our system tracks and analyses "real world" patient treatment outcomes for some of the leading causes of visual impairment, including neovascular age-related macular degeneration (“wet” AMD), choroidal neovascularisation, diabetic retinopathy, retinal vein occlusion, glaucoma, keratoconus, dry eye, uveitis, inherited retinal diseases, and uveal melanoma. The Registries are an international project, and has collected data from Europe, Asia, Africa and North America.
The Save Sight Registeries consist of six registries:
Our registries are immediately relevant to clinicians, researchers, public health providers and policy makers seeking to fight ocular blindness and improve patient outcomes in Australia and internationally.
The Registries' standardised dataset is compliant with international measurement tools for health outcomes (ICHOM) for our neovascular Age-Related Macular Degeneration module and enables current and emerging therapies to be evaluated for clinical efficacy, cost-effectiveness and safety.
Left to right: Mia Rainey, Robert Medynski, Alison Grinyer, Professor Mark Gillies, Dianna Raad, Marco Garcia Molina, Mila Kolmogorova, Getiye Kibret.